Yuji Takeyama

Osaka, 5798026, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Prognostic impact and site-specific efficacy of systemic therapies in locally advanced or metastatic urothelial carcinoma: in an era of expanding therapeutic options.

Prognostic impact and site-specific efficacy of systemic therapies in locally advanced or metastatic urothelial carcinoma: in an era of expanding therapeutic options.

Journal: International journal of clinical oncology

Published: September 08, 2025

Investigation of eligibility for adjuvant therapy from real-world data of patients with urothelial carcinoma undergoing radical cystectomy and radical nephroureterectomy.

Investigation of eligibility for adjuvant therapy from real-world data of patients with urothelial carcinoma undergoing radical cystectomy and radical nephroureterectomy.

Journal: Japanese journal of clinical oncology

Published: September 07, 2023

Trend in overall survival from the start of first-line chemotherapy in patients with metastatic urothelial carcinoma.

Trend in overall survival from the start of first-line chemotherapy in patients with metastatic urothelial carcinoma.

Journal: Japanese journal of clinical oncology

Published: September 07, 2023

Irradiation plus myeloid-derived suppressor cell-targeted therapy for overcoming treatment resistance in immunologically cold urothelial carcinoma.

Irradiation plus myeloid-derived suppressor cell-targeted therapy for overcoming treatment resistance in immunologically cold urothelial carcinoma.

Journal: British journal of cancer

Published: November 19, 2022

A retrospective study on optimal number of cycles of the first-line platinum-based chemotherapy for metastatic urothelial carcinoma.

A retrospective study on optimal number of cycles of the first-line platinum-based chemotherapy for metastatic urothelial carcinoma.

Journal: Urologic oncology

Published: August 06, 2021

Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer.

Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer.

Journal: Cancer letters

Published: October 17, 2019

Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy.

Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy.

Journal: Journal of clinical medicine

Published: October 13, 2018

Steroid sulfatase promotes invasion through epithelial-mesenchymal transition and predicts the progression of bladder cancer.

Steroid sulfatase promotes invasion through epithelial-mesenchymal transition and predicts the progression of bladder cancer.

Journal: Experimental and therapeutic medicine

Published: March 13, 2018

Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma.

Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma.

Journal: International journal of clinical oncology

Published: March 05, 2018

Showing 1-9 of 9

Last Updated: 09/26/2026